{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:50:25Z","timestamp":1776174625014,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Cytogenetic abnormalities are predictors of poor prognosis in multiple myeloma (MM). This paper aims to build and validate a multiparametric conventional and functional whole-body MRI-based prediction model for cytogenetic risk classification in newly diagnosed MM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with newly diagnosed MM who underwent multiparametric conventional whole-body MRI, spinal dynamic contrast-enhanced (DCE-)MRI, spinal diffusion-weighted MRI (DWI) and had genetic analysis were retrospectively included (2011\u20132020\/Ghent University Hospital\/Belgium). Patients were stratified into standard versus intermediate\/high cytogenetic risk groups. After segmentation, 303 MRI features were extracted. Univariate and model-based methods were evaluated for feature and model selection. Testing was performed using receiver operating characteristic (ROC) and precision-recall curves. Models comparing the performance for genetic risk classification of the entire MRI protocol and of all MRI sequences separately were evaluated, including all features. Four final models, including only the top three most predictive features, were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-one patients were enrolled (mean age 66\u2009\u00b1\u20097\u00a0years, 15 men, 13 intermediate-\/high-risk genetics). None of the univariate models and none of the models with all features included achieved good performance. The best performing model with only the three most predictive features and including all MRI sequences reached a ROC-area-under-the-curve of 0.80 and precision-recall-area-under-the-curve of 0.79. The highest statistical performance was reached when all three MRI sequences were combined (conventional whole-body MRI\u2009+\u2009DCE-MRI\u2009+\u2009DWI). Conventional MRI always outperformed the other sequences. DCE-MRI always outperformed DWI, except for specificity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A multiparametric MRI-based model has a better performance in the noninvasive prediction of high-risk cytogenetics in newly diagnosed MM than conventional MRI alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Critical relevance statement<\/jats:title>\n                <jats:p>An elaborate multiparametric MRI-based model performs better than conventional MRI alone for the noninvasive prediction of high-risk cytogenetics in newly diagnosed multiple myeloma; this opens opportunities to assess genetic heterogeneity thus overcoming sampling bias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key points<\/jats:title>\n                <jats:p>\u2022 Standard genetic techniques in multiple myeloma patients suffer from sampling bias due to tumoral heterogeneity.<\/jats:p>\n                <jats:p>\u2022 Multiparametric MRI noninvasively predicts genetic risk in multiple myeloma.<\/jats:p>\n                <jats:p>\u2022 Combined conventional anatomical MRI, DCE-MRI, and DWI had the highest statistical performance to predict genetic risk.<\/jats:p>\n                <jats:p>\u2022 Conventional MRI alone always outperformed DCE-MRI and DWI separately to predict genetic risk. DCE-MRI alone always outperformed DWI separately, except for the parameter specificity to predict genetic risk.<\/jats:p>\n                <jats:p>\u2022 This multiparametric MRI-based genetic risk prediction model opens opportunities to noninvasively assess genetic heterogeneity thereby overcoming sampling bias in predicting genetic risk in multiple myeloma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13244-024-01672-1","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T09:02:26Z","timestamp":1712739746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-8055","authenticated-orcid":false,"given":"Thomas","family":"Van Den Berghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Verberckmoes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Kint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Wallaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Algoet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Behaeghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Dutoit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Van Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Vlummens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Dendooven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Van Dorpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koenraad","family":"Verstraete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"1672_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3863","author":"D Smith","year":"2013","unstructured":"Smith D, Yong K (2013) Multiple myeloma. BMJ. https:\/\/doi.org\/10.1136\/bmj.f3863","journal-title":"BMJ"},{"key":"1672_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.60","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BGM, Rajkumar SV et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. https:\/\/doi.org\/10.1038\/leu.2010.60","journal-title":"Leukemia"},{"key":"1672_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13620","author":"G Pratt","year":"2015","unstructured":"Pratt G, Bowcock S, Chantry A et al (2015) Time to redefine myeloma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.13620","journal-title":"Br J Haematol"},{"key":"1672_CR4","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v5.i3.272","author":"T Derlin","year":"2014","unstructured":"Derlin T, Bannas P (2014) Imaging of multiple myeloma: current concepts. World J Orthop. https:\/\/doi.org\/10.5312\/wjo.v5.i3.272","journal-title":"World J Orthop"},{"key":"1672_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25791","journal-title":"Am J Hematol"},{"key":"1672_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"1672_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"1672_CR8","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.882224","author":"R Fonseca","year":"2014","unstructured":"Fonseca R, Monge J, Dimopoulos MA (2014) Staging and prognostication of multiple myeloma. Expert Rev Hematol. https:\/\/doi.org\/10.1586\/17474086.2014.882224","journal-title":"Expert Rev Hematol"},{"key":"1672_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.09.004","author":"H Paszekova","year":"2014","unstructured":"Paszekova H, Kryukov F, Kubiczkova L et al (2014) High-risk multiple myeloma: different definitions, different outcomes? Clin Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2013.09.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1672_CR10","doi-asserted-by":"publisher","DOI":"10.5644\/ama2006-124.242","author":"O Castaneda","year":"2019","unstructured":"Castaneda O, Baz R (2019) Multiple myeloma genomics - a concise review. Acta Med Acad. https:\/\/doi.org\/10.5644\/ama2006-124.242","journal-title":"Acta Med Acad"},{"key":"1672_CR11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070209-175325","author":"J Laubach","year":"2011","unstructured":"Laubach J, Richardson P, Anderson K (2011) Multiple myeloma. Annu Rev Med. https:\/\/doi.org\/10.1146\/annurev-med-070209-175325","journal-title":"Annu Rev Med"},{"key":"1672_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13038","author":"H Fairfield","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR (2016) Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. https:\/\/doi.org\/10.1111\/nyas.13038","journal-title":"Ann N Y Acad Sci"},{"key":"1672_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02725-3","author":"CM Sch\u00fcrch","year":"2020","unstructured":"Sch\u00fcrch CM, Rasche L, Frauenfeld L et al (2020) A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-019-02725-3","journal-title":"Virchows Arch"},{"key":"1672_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012","author":"K Brigle","year":"2017","unstructured":"Brigle K, Rogers B (2017) Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. https:\/\/doi.org\/10.1016\/j.soncn.2017.05.012","journal-title":"Semin Oncol Nurs"},{"key":"1672_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.24402","journal-title":"Am J Hematol"},{"key":"1672_CR16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.081083","author":"S Van Wier","year":"2013","unstructured":"Van Wier S, Braggio E, Baker A et al (2013) Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2012.081083","journal-title":"Haematologica"},{"key":"1672_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2229","author":"NV Smadja","year":"2001","unstructured":"Smadja NV, Bastard C, Brigaudeau C et al (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. https:\/\/doi.org\/10.1182\/blood.V98.7.2229","journal-title":"Blood"},{"key":"1672_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-021-01388-y","author":"J Liu","year":"2021","unstructured":"Liu J, Wang C, Guo W et al (2021) A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma. Radiol Med. https:\/\/doi.org\/10.1007\/s11547-021-01388-y","journal-title":"Radiol Med"},{"key":"1672_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V et al (2013) Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013. Mayo Clin Proc. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.019","journal-title":"Mayo Clin Proc"},{"key":"1672_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. https:\/\/doi.org\/10.1182\/blood-2016-01-631200","journal-title":"Blood"},{"key":"1672_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0368-z","author":"HSH Chan","year":"2017","unstructured":"Chan HSH, Chen CI, Reece DE (2017) Current review on high-risk multiple myeloma. Curr Hematol Malig Rep. https:\/\/doi.org\/10.1007\/s11899-017-0368-z","journal-title":"Curr Hematol Malig Rep"},{"key":"1672_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00679-5","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K (2022) High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-022-00679-5","journal-title":"Blood Cancer J"},{"key":"1672_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J et al (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. https:\/\/doi.org\/10.1038\/leu.2009.174","journal-title":"Leukemia"},{"key":"1672_CR24","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603","author":"SK Kumar","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. https:\/\/doi.org\/10.4065\/mcp.2009.0603","journal-title":"Mayo Clin Proc"},{"key":"1672_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93835-z","author":"E Kriegova","year":"2021","unstructured":"Kriegova E, Fillerova R, Minarik J et al (2021) Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-93835-z","journal-title":"Sci Rep"},{"key":"1672_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ et al (2022) Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.21.02614","journal-title":"J Clin Oncol"},{"key":"1672_CR27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24893","author":"RW Jansen","year":"2018","unstructured":"Jansen RW, van Amstel P, Martens RM et al (2018) Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.24893","journal-title":"Oncotarget"},{"key":"1672_CR28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M et al (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2014.117176","journal-title":"Haematologica"},{"key":"1672_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702896","author":"A Palumbo","year":"2001","unstructured":"Palumbo A, Anderson K (2001) Multiple myeloma. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/sj.bmt.1702896","journal-title":"Bone Marrow Transplant"},{"key":"1672_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2015.02.013","author":"SL Giles","year":"2015","unstructured":"Giles SL, Desouza NM, Collins DJ et al (2015) Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Clin Radiol. https:\/\/doi.org\/10.1016\/j.crad.2015.02.013","journal-title":"Clin Radiol"},{"key":"1672_CR31","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2010.0013","author":"CD Collins","year":"2010","unstructured":"Collins CD (2010) Multiple myeloma. Cancer Imaging. https:\/\/doi.org\/10.1102\/1470-7330.2010.0013","journal-title":"Cancer Imaging"},{"key":"1672_CR32","doi-asserted-by":"publisher","DOI":"10.1055\/a-0864-2084","author":"A Kosmala","year":"2019","unstructured":"Kosmala A, Bley T, Petritsch B (2019) Imaging of Multiple Myeloma Bildgebende Diagnostik des Multiplen Myeloms. Rofo. https:\/\/doi.org\/10.1055\/a-0864-2084","journal-title":"Rofo"},{"key":"1672_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2310","author":"J Hillengass","year":"2009","unstructured":"Hillengass J, Zechmann C, B\u00e4uerle T et al (2009) Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2310","journal-title":"Clin Cancer Res"},{"key":"1672_CR34","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.740559","author":"J Hillengass","year":"2013","unstructured":"Hillengass J, Landgren O (2013) Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging early myeloma. Leuk Lymphoma. https:\/\/doi.org\/10.3109\/10428194.2012.740559","journal-title":"Leuk Lymphoma"},{"key":"1672_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2009.03.045","author":"GP Schmidt","year":"2009","unstructured":"Schmidt GP, Reiser MF, Baur-Melnyk A (2009) Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol. https:\/\/doi.org\/10.1016\/j.ejrad.2009.03.045","journal-title":"Eur J Radiol"},{"key":"1672_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2015.11.040","author":"JC Dutoit","year":"2016","unstructured":"Dutoit JC, Claus E, Offner F et al (2016) Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma. Eur J Radiol. https:\/\/doi.org\/10.1016\/j.ejrad.2015.11.040","journal-title":"Eur J Radiol"},{"key":"1672_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-014-3324-5","author":"JC Dutoit","year":"2014","unstructured":"Dutoit JC, Vanderkerken MA, Anthonissen J et al (2014) The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-014-3324-5","journal-title":"Eur Radiol"},{"key":"1672_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s13244-016-0492-7","author":"JC Dutoit","year":"2016","unstructured":"Dutoit JC, Verstraete KL (2016) MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging. https:\/\/doi.org\/10.1007\/s13244-016-0492-7","journal-title":"Insights Imaging"},{"key":"1672_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-017-2609-6","author":"JC Dutoit","year":"2017","unstructured":"Dutoit JC, Verstraete KL (2017) Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Skeletal Radiol. https:\/\/doi.org\/10.1007\/s00256-017-2609-6","journal-title":"Skeletal Radiol"},{"key":"1672_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2013.04.012","author":"JC Dutoit","year":"2013","unstructured":"Dutoit JC, Vanderkerken MA, Verstraete KL (2013) Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. Eur J Radiol. https:\/\/doi.org\/10.1016\/j.ejrad.2013.04.012","journal-title":"Eur J Radiol"},{"key":"1672_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M (2015) Multiple myeloma. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1","journal-title":"Lancet"},{"key":"1672_CR42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0675","author":"N Van Roy","year":"2017","unstructured":"Van Roy N, Van Der Linden M, Menten B et al (2017) Shallow whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma patients. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0675","journal-title":"Clin Cancer Res"},{"key":"1672_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113800","author":"T Sante","year":"2014","unstructured":"Sante T, Vergult S, Volders PJ et al (2014) ViVar: a comprehensive platform for the analysis and visualization of structural genomic variation. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0113800","journal-title":"PLoS One"},{"key":"1672_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp132","author":"MA van de Wiel","year":"2009","unstructured":"van de Wiel MA, Brosens R, Eilers PHC et al (2009) Smoothing waves in array CGH tumor profiles. Bioinformatics. https:\/\/doi.org\/10.1093\/bioinformatics\/btp132","journal-title":"Bioinformatics"},{"key":"1672_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxh008","author":"AB Olshen","year":"2004","unstructured":"Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. https:\/\/doi.org\/10.1093\/biostatistics\/kxh008","journal-title":"Biostatistics"},{"key":"1672_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-021-03754-3","author":"MJ Fitzpatrick","year":"2022","unstructured":"Fitzpatrick MJ, Nardi V, Sohani AR (2022) Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiol. https:\/\/doi.org\/10.1007\/s00256-021-03754-3","journal-title":"Skeletal Radiol"},{"key":"1672_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0183-0","author":"J Schecter","year":"2013","unstructured":"Schecter J, Lentzsch S (2013) Multiple myeloma: defining the high-risk patient and determining the optimal treatment strategy. Curr Hematol Malig Rep. https:\/\/doi.org\/10.1007\/s11899-013-0183-0","journal-title":"Curr Hematol Malig Rep"},{"key":"1672_CR48","doi-asserted-by":"publisher","DOI":"10.1148\/rg.297095050","author":"Y Morag","year":"2009","unstructured":"Morag Y, Morag-Hezroni M, Jamadar DA et al (2009) Bisphosphonate related osteonecrosis of the jaw: a pictorial review. Radiographics. https:\/\/doi.org\/10.1148\/rg.297095050","journal-title":"Radiographics"},{"key":"1672_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.018","author":"NS Joseph","year":"2017","unstructured":"Joseph NS, Gentili S, Kaufman JL et al (2017) SOHO supplement 2017 high-risk multiple myeloma: definition and management. Clin Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2017.02.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1672_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22874","author":"SC Smith","year":"2020","unstructured":"Smith SC, Althof PA, Dave BJ, Sanmann JN (2020) High-risk cytogenetics in multiple myeloma: further scrutiny of deletions within the IgH gene region enhances risk stratification. Genes Chromosom Cancer. https:\/\/doi.org\/10.1002\/gcc.22874","journal-title":"Genes Chromosom Cancer"},{"key":"1672_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00631-7","author":"N Marneni","year":"2021","unstructured":"Marneni N, Chakraborty R (2021) Current approach to managing patients with newly diagnosed high-risk multiple myeloma. Curr Hematol Malig Rep. https:\/\/doi.org\/10.1007\/s11899-021-00631-7","journal-title":"Curr Hematol Malig Rep"},{"key":"1672_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03353-5","author":"I Hanamura","year":"2022","unstructured":"Hanamura I (2022) Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-022-03353-5","journal-title":"Int J Hematol"},{"key":"1672_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081961","author":"H Awada","year":"2021","unstructured":"Awada H, Thapa B, Awada H et al (2021) A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics. Cells. https:\/\/doi.org\/10.3390\/cells10081961","journal-title":"Cells"},{"key":"1672_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcm.2016.02.012","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012","journal-title":"J Chiropr Med"},{"key":"1672_CR55","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-3652.2014.03.01","author":"Y Gordon","year":"2014","unstructured":"Gordon Y, Partovi S, M\u00fcller-Eschner M et al (2014) Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc Diagn Ther. https:\/\/doi.org\/10.3978\/j.issn.2223-3652.2014.03.01","journal-title":"Cardiovasc Diagn Ther"},{"key":"1672_CR56","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/55166688","author":"JPB O\u2019Connor","year":"2011","unstructured":"O\u2019Connor JPB, Tofts PS, Miles KA et al (2011) Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr\/55166688","journal-title":"Br J Radiol"},{"key":"1672_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2010.03.011","author":"A Biffar","year":"2010","unstructured":"Biffar A, Dietrich O, Sourbron S et al (2010) Diffusion and perfusion imaging of bone marrow. Eur J Radiol. https:\/\/doi.org\/10.1016\/j.ejrad.2010.03.011","journal-title":"Eur J Radiol"},{"key":"1672_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.22861","author":"SP Sourbron","year":"2011","unstructured":"Sourbron SP, Buckley DL (2011) On the scope and interpretation of the Tofts models for DCE-MRI. Magn Reson Med. https:\/\/doi.org\/10.1002\/mrm.22861","journal-title":"Magn Reson Med"},{"key":"1672_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","author":"PS Tofts","year":"1999","unstructured":"Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/(SICI)1522-2586(199909)10:3%3c223::AID-JMRI2%3e3.0.CO;2-S","journal-title":"J Magn Reson Imaging"},{"key":"1672_CR60","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170389","author":"V Koutoulidis","year":"2018","unstructured":"Koutoulidis V, Papanikolaou N, Moulopoulos LA (2018) Functional and molecular MRI of the bone marrow in multiple myeloma. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr.20170389","journal-title":"Br J Radiol"},{"key":"1672_CR61","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.13.11818","author":"SY Park","year":"2014","unstructured":"Park SY, Kim CK, Park BK (2014) Comparison of apparent diffusion coefficient calculation between two-point and multipoint b value analyses in prostate cancer and benign prostate tissue at 3 T: preliminary experience. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/AJR.13.11818","journal-title":"AJR Am J Roentgenol"},{"key":"1672_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2005.01.017","author":"A Baur-Melnyk","year":"2005","unstructured":"Baur-Melnyk A, Buhmann S, D\u00fcrr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol. https:\/\/doi.org\/10.1016\/j.ejrad.2005.01.017","journal-title":"Eur J Radiol"},{"key":"1672_CR63","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.167.4.8819407","author":"A St\u00e4bler","year":"1996","unstructured":"St\u00e4bler A, Baur A, Bartl R et al (1996) Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/ajr.167.4.8819407","journal-title":"AJR Am J Roentgenol"},{"key":"1672_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.mric.2007.03.002","author":"F Alyas","year":"2007","unstructured":"Alyas F, Saifuddin A, Connell D (2007) MR imaging evaluation of the bone marrow and marrow infiltrative disorders of the lumbar spine. Magn Reson Imaging Clin N Am. https:\/\/doi.org\/10.1016\/j.mric.2007.03.002","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"1672_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3333","author":"O Dietrich","year":"2017","unstructured":"Dietrich O, Geith T, Reiser MF, Baur-Melnyk A (2017) Diffusion imaging of the vertebral bone marrow. NMR Biomed. https:\/\/doi.org\/10.1002\/nbm.3333","journal-title":"NMR Biomed"},{"key":"1672_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10818","author":"A Baur","year":"2002","unstructured":"Baur A, St\u00e4bler A, Nagel D et al (2002) Magnetic resonance imaging as a supplement for the clinical staging system of durie and salmon? Cancer. https:\/\/doi.org\/10.1002\/cncr.10818","journal-title":"Cancer"},{"key":"1672_CR67","doi-asserted-by":"publisher","DOI":"10.2307\/2346101","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. https:\/\/doi.org\/10.2307\/2346101","journal-title":"J R Stat Soc"},{"key":"1672_CR68","doi-asserted-by":"publisher","unstructured":"Haibo H, Yang B, Garcia EA, Shutao L (2008) ADASYN: adaptive synthetic sampling approach for imbalanced learning. In: 2008 IEEE International Joint Conference on Neural Networks (IEEE World Congress on Computational Intelligence). IEEE. https:\/\/doi.org\/10.1109\/IJCNN.2008.4633969","DOI":"10.1109\/IJCNN.2008.4633969"},{"key":"1672_CR69","doi-asserted-by":"publisher","unstructured":"Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology. https:\/\/doi.org\/10.1148\/radiol.2015151169","DOI":"10.1148\/radiol.2015151169"},{"key":"1672_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27637","author":"J Liu","year":"2021","unstructured":"Liu J, Zeng P, Guo W et al (2021) Prediction of high-risk cytogenetic status in multiple myeloma based on magnetic resonance imaging: utility of radiomics and comparison of machine learning methods. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/jmri.27637","journal-title":"J Magn Reson Imaging"},{"key":"1672_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23258","author":"LA Moulopoulos","year":"2012","unstructured":"Moulopoulos LA, Dimopoulos MA, Kastritis E et al (2012) Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.23258","journal-title":"Am J Hematol"},{"key":"1672_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.70","author":"LA Moulopoulos","year":"2010","unstructured":"Moulopoulos LA, Dimopoulos MA, Christoulas D et al (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia. https:\/\/doi.org\/10.1038\/leu.2010.70","journal-title":"Leukemia"},{"key":"1672_CR73","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2016160363","author":"V Koutoulidis","year":"2017","unstructured":"Koutoulidis V, Fontara S, Terpos E et al (2017) Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology. https:\/\/doi.org\/10.1148\/radiol.2016160363","journal-title":"Radiology"},{"key":"1672_CR74","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2018.11163","author":"RH Basiouny","year":"2018","unstructured":"Basiouny RH, Hendy AA, Khattab RT (2018) Diffusion weighted image MRI in assessment of patients with multiple myeloma. Egypt J Hosp Med. https:\/\/doi.org\/10.21608\/ejhm.2018.11163","journal-title":"Egypt J Hosp Med"},{"key":"1672_CR75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5803","author":"R Walker","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2006.08.5803","journal-title":"J Clin Oncol"},{"key":"1672_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23455","author":"J Hillengass","year":"2008","unstructured":"Hillengass J, Zechmann CM, Nadler A et al (2008) Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.23455","journal-title":"Int J Cancer"},{"key":"1672_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-019-02028-w","author":"Z Bodalal","year":"2019","unstructured":"Bodalal Z, Trebeschi S, Nguyen-Kim TDL et al (2019) Radiogenomics: bridging imaging and genomics. Abdom Radiol (NY). https:\/\/doi.org\/10.1007\/s00261-019-02028-w","journal-title":"Abdom Radiol (NY)"},{"key":"1672_CR78","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019181949","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology. https:\/\/doi.org\/10.1148\/radiol.2019181949","journal-title":"Radiology"},{"key":"1672_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2020.10.005","author":"A Latifoltojar","year":"2021","unstructured":"Latifoltojar A, Boyd K, Riddell A et al (2021) Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: towards macro-phenotype driven patient management. Magn Reson Imaging. https:\/\/doi.org\/10.1016\/j.mri.2020.10.005","journal-title":"Magn Reson Imaging"},{"key":"1672_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27934","author":"M Sun","year":"2022","unstructured":"Sun M, Cheng J, Ren C et al (2022) Differentiation of diffuse infiltration pattern in multiple myeloma from hyperplastic hematopoietic bone marrow: qualitative and quantitative analysis using whole-body MRI. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/jmri.27934","journal-title":"J Magn Reson Imaging"},{"key":"1672_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-4195-0","author":"EK Mai","year":"2016","unstructured":"Mai EK, Hielscher T, Kloth JK et al (2016) Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-015-4195-0","journal-title":"Eur Radiol"},{"key":"1672_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051248","author":"L Rasche","year":"2019","unstructured":"Rasche L, Kort\u00fcm KM, Raab MS, Weinhold N (2019) The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20051248","journal-title":"Int J Mol Sci"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-024-01672-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T09:02:43Z","timestamp":1712739763000},"score":1,"resource":{"primary":{"URL":"https:\/\/insightsimaging.springeropen.com\/articles\/10.1186\/s13244-024-01672-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1672"],"URL":"https:\/\/doi.org\/10.1186\/s13244-024-01672-1","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval [EC2019-1267(BC-06060)\/1268(BC-06063)] and written informed consent were obtained for retrospective pseudonymized data usage by the Institutional Review Board of the Ghent University Hospital (B-9000-Ghent, Belgium).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Declarations of interest: the authors declare that they have no competing interests.The authors of this manuscript declare no financial or personal relationships with any companies or individuals, whose products or services may be related to the subject matter of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}